Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $216.6 million.

  • BridgeBio Pharma's Total Current Liabilities rose 5558.56% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year increase of 5558.56%. This contributed to the annual value of $154.4 million for FY2024, which is 733.85% up from last year.
  • BridgeBio Pharma's Total Current Liabilities amounted to $216.6 million in Q3 2025, which was up 5558.56% from $175.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Total Current Liabilities' 5-year high stood at $216.6 million during Q3 2025, with a 5-year trough of $94.7 million in Q1 2021.
  • For the 5-year period, BridgeBio Pharma's Total Current Liabilities averaged around $132.3 million, with its median value being $134.4 million (2024).
  • In the last 5 years, BridgeBio Pharma's Total Current Liabilities tumbled by 2198.92% in 2023 and then skyrocketed by 5558.56% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Total Current Liabilities (Quarter) stood at $135.1 million in 2021, then decreased by 10.1% to $121.4 million in 2022, then grew by 18.46% to $143.8 million in 2023, then grew by 7.34% to $154.4 million in 2024, then surged by 40.28% to $216.6 million in 2025.
  • Its Total Current Liabilities was $216.6 million in Q3 2025, compared to $175.9 million in Q2 2025 and $152.1 million in Q1 2025.